1-(3-4-methylendioxybenzyl)piperazine (MDBZP)

Pre-Review Report

Expert Committee on Drug Dependence
Thirty-fifth Meeting
Hammamet, Tunisia, 4-8 June 2012
1-(3,4-methylendioxybenzyl)piperazine (MDBZP)
Acknowledgements

This report has been drafted under the responsibility of the WHO Secretariat, Essential Medicines and Health Products, Medicines Access and Rational Use Unit. The WHO Secretariat would like to thank the following people for their contribution in producing this pre-review report: Dr Simon Elliott, United Kingdom (literature review and drafting), Dr Caroline Bodenschatz (editing) and Mr Kamber Celebi, France (questionnaire report).
ECDD (2012) Agenda item 5.3e

1-(3,4-methylendioxybenzyl)piperazine (MDBZP)
## Contents

SUMMARY ................................................................................................................................. 7

1. Substance identification ........................................................................................................ 8
   A. International Nonproprietary Name (INN) ........................................................................ 8
   B. Chemical Abstract Service (CAS) Registry Number .......................................................... 8
   C. Other Names ..................................................................................................................... 8
   D. Trade Names ................................................................................................................... 8
   E. Street Names ................................................................................................................... 8
   F. Physical properties .......................................................................................................... 8
   G. WHO Review History ..................................................................................................... 8

2. Chemistry ............................................................................................................................... 8
   A. Chemical Name ................................................................................................................ 8
   B. Chemical Structure .......................................................................................................... 8
   C. Stereoisomers .................................................................................................................. 9
   D. Synthesis ......................................................................................................................... 9
   E. Chemical description ...................................................................................................... 9
   F. Chemical properties ...................................................................................................... 9
   G. Chemical identification ................................................................................................. 9

3. Ease of convertibility into controlled substances ................................................................. 9

4. General pharmacology ......................................................................................................... 9
   4.1. Pharmacodynamics ....................................................................................................... 9
   4.2. Routes of Administration ............................................................................................ 10
   4.3. Pharmacokinetics ......................................................................................................... 10

5. Toxicology ............................................................................................................................ 11

6. Adverse reactions in humans .............................................................................................. 11

7. Dependence potential .......................................................................................................... 11

8. Abuse potential .................................................................................................................... 11

9. Therapeutic applications, extent of therapeutic use and epidemiology of medical use ... 11

10. Listing on the WHO Model List of Essential Medicines .................................................. 11

11. Marketing authorizations (as a medicine) .......................................................................... 11

12. Industrial use ..................................................................................................................... 11

13. Non-medical use, abuse and dependence ........................................................................ 12


15. Licit production, consumption and international trade .................................................... 12
16. Illicit manufacture and traffic and related information ....................................................... 12
17. Current international controls and their impact................................................................. 12
18. Current and past national controls ...................................................................................... 12
19. Other medical and scientific matters relevant for a recommendation on the scheduling of
    the substance .................................................................................................................. 12

References .......................................................................................................................... 13

Annex 1: WHO Questionnaire For Review Of Psychoactive Substances For The 35th ECDD:
1-(3-4-Methylendioxybenzyl) Piperazine (MDBZP) .................................................................. 15
Summary

There is very little information available for 1-(3,4-methylenedioxybenzyl)piperazine (MDBZP or MDBP). It is a piperazine derivative but its effects are largely unknown. MDBZP has never been licensed as a medicine but is a metabolite of a withdrawn nootropic medicine, fipexide. This was withdrawn due to adverse toxic effects (fever and hepatotoxicity). Use of MDBZP has been noted by governmental organizations in the USA but there are no reports for other countries. The mode of abuse is believed to be similar to that of “Ecstasy” with many users seeking MDMA-like effects, particularly with concomitant BZP or TFMPP use. There are no published non-fatal or fatal hospital admissions. No specific studies have been performed to determine the abuse or dependence potential of MDBZP.
1. **Substance identification**

   A. **International Nonproprietary Name (INN)**
      
      Not applicable.

   B. **Chemical Abstract Service (CAS) Registry Number**
      
      Free base: 32231-06-4

   C. **Other Names**
      
      1-(3,4-methylenedioxybenzyl)piperazine, 3,4-methylenedioxybenzylpiperazine, 1-piperonypiperazine, piperonylpiperazine, methylenedioxybenzylpiperazine, MDBZP, 1-(benzo[1,3]dioxol-5-ylmethyl)piperazine, MDBP.

   D. **Trade Names**
      
      KRKA (refer annex 1).

   E. **Street Names**
      
      MDBZP is not known to be associated with any particular street names.

   F. **Physical properties**
      
      White to yellow or yellow-brownish crystal solid.

   G. **WHO Review History**
      
      Several reports suggest misuse of MDBZP over the last years. At the time being, neither BZP nor any other substituted piperazine is listed in the Schedules of the United Nations 1971 Convention on Psychotropic Substances. In order to bring more conclusive scientific evidence on the overall risks of MDBZP for an eventual international scheduling, the WHO Secretariat has decided to initiate at the 35th ECDD a pre-review.

2. **Chemistry**

   A. **Chemical Name**
      
      IUPAC Name: 1-(benzo[1,3]dioxol-5-ylmethyl)piperazine
      
      CA Index Name: 1-(benzo[1,3]dioxol-5-ylmethyl)piperazine

   B. **Chemical Structure**
      
      Free base:
35th ECDD (2012) Agenda item 5.3e 1-(3,4-methylendioxybenzyl)piperazine (MDBZP)

Molecular Formula: $\text{C}_{12}\text{H}_{16}\text{N}_2\text{O}_2$
Molecular Weight: 220.27 g/mol (free base)
Melting point: 36-40 °C (lit.)
Boiling point: 147-149 °C (lit.)
Fusion point: 158.4 °C (lit.)

C. **Stereoisomers**
MDBZP has no chiral centres and therefore no stereoisomers.

D. **Synthesis**
MDBZP is an entirely synthetic compound but the exact manufacturing process is not known.

E. **Chemical description**
MDBZP is a substituted piperazine, with a methylenedioxy-moiety as per the structure of MDMA. MDBZP shares the same substitutions on the benzene ring as methylenedioxyamphetamine (MDA).

F. **Chemical properties**
No information.

G. **Chemical identification**
Methods for the identification of MDBZP have been provided by Wohlfarth et al. (2010) and Abdel-Hay et al. (2011).

3. **Ease of convertibility into controlled substances**
No information available.
No study data available.

4. **General pharmacology**

4.1. **Pharmacodynamics**

*Neuropharmacology and effects on central nervous system*
No studies have been performed using MDBZP itself but MDBZP is a primary and proposed active metabolite of fipexide which has been shown to increase noradrenaline in animals and to have dopaminergic effects (Stancheva et al., 1993; Lucchi et al., 1986; Rolandi et al., 1984).

**Effects on cardiovascular, respiratory, gastrointestinal, liver, kidneys and genitourinary systems**
No study data available.

**Behavioural studies in animals**
No study data available.

**Effects on cognition and behaviour in humans**
No study data are available for MDBZP. However, a parent substance, fipexide, has shown some positive cognitive effects (e.g. memory and attention) (Bompani and Scali, 1986). There are no published, unpublished or anecdotal reports of the effects of MDBZP. In particular, no user reports are presented on common Internet sites (Erowid and The Lycaeum).

**Effects in humans**
No study data are available for MDBZP. However, a parent substance, fipexide, has shown some positive cognitive effects (e.g. memory and attention) (Bompani and Scali, 1986). There are no published, unpublished or anecdotal reports of the effects of MDBZP. In particular, no user reports are presented on common Internet sites (Erowid and The Lycaeum).

**Interactions with other substances and medicines**
Although MDBZP may affect the monoamine systems, there are no specific data and therefore it is difficult to determine any potential interactions with other substances or medicines.

### 4.2. Routes of Administration

There is no information available about route of administration and dosage.

### 4.3. Pharmacokinetics

In rats, studies have indicated that MDBZP is metabolized by demethylenation and subsequent methylation to N-(4-hydroxy-3-methoxybenzyl)piperazine followed by partial glucuronidation or sulfation (Staack and Maurer, 2004a; Maurer et al., 2004). Additionally, researchers found degradation of the piperazine moiety to N-(3,4-methylenedioxybenzyl)ethylenediamine and 3,4-methylenedioxybenzylamine and N-dealkylation to piperazine (Staack and Maurer, 2004a). Furthermore, MDBZP is a primary metabolite of fipexide which is also metabolised to 4-chlorophenoxyacetic acid, 1-[2-(4-chlorophenoxy)acetyl]piperazine, N-(4-hydroxy-3-methoxybenzyl)piperazine, piperazine, N-(3,4-methylenedioxybenzyl)ethylenediamine, and N-[2-(4-chlorophenoxy)acetyl]ethylenediamine (Staack and Maurer, 2004b; Sleno et al., 2007).
5. Toxicology

There are no published pre-clinical safety data available concerning the toxicity, reproductive impact and mutagenic/carcinogenic potential of MDBZP. Furthermore, there are no user reports (published or anecdotal) regarding its use, nor are there any published or reported cases of intoxication.

6. Adverse reactions in humans

Of indirect relevance, fipexide use has been reported to result in fever and serious liver cell necrosis and fulminant liver failure (Guy et al., 1990; Durand et al., 1992). There are no study data to suggest or confirm that MDBZP (as an active metabolite) was the cause of these effects.

7. Dependence potential

No study data available.

8. Abuse potential

No study data available.

9. Therapeutic applications, extent of therapeutic use and epidemiology of medical use

MDBZP has not been used in therapy. As described elsewhere, fipexide was a nootropic used in the treatment of cognitive disorders (Bompani and Scali, 1986) but was later withdrawn due to its adverse effects (particularly hepatic toxicity).

10. Listing on the WHO Model List of Essential Medicines

MDBZP is not listed on the WHO Model List of Essential Medicines.

11. Marketing authorizations (as a medicine)

Based on the WHO questionnaire in 2008 for review of psychoactive substances for 35th ECDD (annexe 1), of the 59 countries that responded, only Mongolia authorized MDBP as a medical or veterinary product. The brand name is "KRKA" and reported its "indication" to be "Fluphenazine deconcate", and also off-label use as "Moditen depo". The dosage is 25 mg/ml and it is in ampoule form. Brunei, Mongolia and Tuvalu indicated that they import the substance.

12. Industrial use
MDBZP has no industrial use.

13. **Non-medical use, abuse and dependence**

MDBZP use has been mentioned in the USA (DEA, 2004). There is no information available about route of administration and dosage.

Of the 59 countries responding to the WHO questionnaire for review of psychoactive substances for the 35th ECDD, 19 countries reported that the substance is not used in a harmful way and 14 countries have no information on the abuse of the substance.

14. **Nature and magnitude of public health problems related to abuse and dependence**

As for BZP and TFMPP, MDBZP use appears to be associated with situations similar to that of “Ecstasy”, or with users who are seeking effects similar to “Ecstasy” (MDMA in particular) and therefore instances of misuse, abuse and dependence would be limited to such individuals rather than the general population (DEA, 2004). The mode of use could involve the combinational use (intentionally or unintentionally) of other piperazine-derivatives (e.g. BZP) or other substances. No fatal or non-fatal intoxications of MDBZP (with or without other substances) have been reported.

15. **Licit production, consumption and international trade**

Not applicable.

16. **Illicit manufacture and traffic and related information**

Besides Mongolia there are no other countries who have tracked illicit activities involving the substance. Mongolia reported clandestine manufacturing and also smuggling (Annex 1).

17. **Current international controls and their impact**

Not applicable in relation to affecting impact of medical use.

18. **Current and past national controls**

The WHO questionnaire for review of psychoactive substances in 2008 (annex 1) found that Denmark, Japan, Mongolia and Tuvalu controlled MDBP under legislation that is intended to regulate availability of substances of abuse. In Japan MDBP is controlled as designated substances under the Pharmaceutical Affairs Law in Japan since January 2008.

19. **Other medical and scientific matters relevant for a recommendation on the scheduling of the substance**

No data.
References

Abdel-Hay, KM., Awad, T., Deruiter, J. and Clark, CR. (2011) Differentiation of methylenedioxybenzylpiperazines (MDBPs) and methoxymethylbenzylpiperazines (MMBPs) By GC-IRD and GC-MS. Forensic Sci Int. 210(1-3), 122-8


ANNEX 1: WHO Questionnaire for Review of Psychoactive Substances for the 35th ECDD: 1-(3,4-methylendioxybenzyl) piperazine (MDBZP)

The 2008 WHO questionnaire for the preparation of the thirty-fifth Expert Committee on Drug Dependence was responded for MDBP by 59 countries.

LEGITIMATE USE

Of the responded countries only Mongolia authorized MDBP as a medical or veterinary product and the USA legitimated TFMPP for technical use only. There are no countries where other legitimate use is reported. The substance is granted market admission since 1995 in Mongolia under the brand name "KRKA" and reported its "indication" to be "Fluphenazine deconcate", and also off-label use as "Moditen depo". The dosage is 25 mg/ml and it is in ampoule form. 3 countries indicated that they import the substance. These are Brunei, Mongolia and Tuvalu.

ABUSE

Of the 59 countries responding, 19 countries reported that the substance is not used in a harmful way and 14 countries have no information on the abuse of the substance.

CONTROL

Denmark, Japan, Mongolia and Tuvalu reported that MDBP is controlled under legislation that is intended to regulate availability of substances of abuse. In Japan MDBP is controlled as designated substances under the Pharmaceutical Affairs Law in Japan since January 2008. Besides Mongolia there are no other countries who have tracked illicit activities involving the substance. They reported clandestine manufacturing and also smuggling is reported. There are no reports on the quantity of the seizures.

IMPACT OF SCHEDULING

Scheduling is unlikely to have any impact on human and animal medical care

Brand Name
KRKA

Form
Ampoule 25mg/ml

Technical Use
Industrial use